Patricia Inácio, PhD, science writer —

A next-generation vest to help clear airway mucus in adults and children with cystic fibrosis (CF) or other lung disorders has been launched by its maker, Baxter International. Called The Vest Advanced Pulmonary Experience (APX), the garment was redesigned in consultation with clinicians and patients, and incorporates the…

About half of cystic fibrosis (CF) patients had used, were using, or were interested in using cannabidiol (CBD), the main active compounds found in the cannabis plant, according to a new survey and analysis conducted at a U.S. center. “Cannabidiol is used to treat a variety of symptoms including…

The Rare Disease Cures Accelerator-Data and Analytics Platform — dubbed RDCA–DAP — has received new datasets that promise to accelerate research and the development of new therapies for cystic fibrosis (CF). The data was generated by the Cystic Fibrosis Therapeutics Development Network (TDN), known for its clinical trials…

A 3-year-old boy who carries a new combination of two mutations in the CFTR gene, but with no clinical signs of cystic fibrosis (CF), was described by researchers in a case report. “The case presented has no clinical symptoms so far and doesn’t meet the criteria for a…

A new small molecule, called VOMG, showed good antimicrobial activity against Mycobacterium abscessus, a bacterium that can cause serious infections in people with cystic fibrosis (CF). “The bactericidal and eradicating properties of VOMG … strongly reinforce the potential of VOMG in the treatment of pulmonary infections especially in CF individuals,…

Men and patients diagnosed with cystic fibrosis (CF) earlier in life have higher lung function and greater lung function variability, according an analysis spanning over 20 years of data from the U.K. Cystic Fibrosis Registry. Lung function variability increased in men and women with CF after age 40, a…

Destiny Pharma is launching a research program to test a potential therapy derived from its XF drug platform for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). The program will test the potency of an experimental treatment known as XF-73 in MRSA samples from CF…

Combining telehealth with home spirometry to assess lung function, along with some in-person visits to the doctor’s office, was as effective as in-person visits only to manage cystic fibrosis (CF) in children, a Swedish study reported. The findings suggest “that it may be safe to introduce telemedicine and home…

Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly lowered several pro-inflammatory blood markers with as early as one month of use in cystic fibrosis (CF) patients carrying F508del — the most common CF-causing mutation — and in parallel with gains in lung function. These are the findings of a small study that suggest…

Vertex Pharmaceuticals and England’s National Health Service (NHS) have reached an agreement that allows all current and future eligible cystic fibrosis (CF) patients to access three of the company’s approved CFTR modulators at low or no out-of-pocket cost. Kaftrio (elexacaftor/tezacaftor/ivacaftor, sold as Trikafta in the U.S.), Symkevi (tezacaftor/ivacaftor,…